Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07242417RecruitingEarly Phase 1
TC-G203 for adults with GPC3-positive advanced solid tumors
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07244328RecruitingEarly Phase 1
UX-GIP001 cell therapy for drug-resistant temporal lobe epilepsy
This trial tests a new cell therapy, UX-GIP001, for people whose seizures start in one small area of the brain (the mesial temporal lobe) and are not controlled by at least two seizure medications. The goal is to see if this treatment can safely reduce seizures.
Hangzhou, ZhejiangAges 18–75 - NCT07240207Recruiting
Studying immune cells in children's solid tumors
This trial analyzes the tumor environment in children with solid tumors to find better ways to use immune cells for treatment. It may help develop new cell-based therapies tailored to each child's tumor.
Pavia, PaviaAges 1 day–18 years - NCT07247396RecruitingPhase 1
CEA CAR-T therapy after surgery for colorectal cancer spread
This trial tests a special immune cell therapy (CAR-T) that targets a protein called CEA on cancer cells. It is for people with colorectal cancer that has spread to the lining of the belly (peritoneum) and who have already had surgery to remove as much of the spread as possible.
Hangzhou, ZhejiangAges 18–75 - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT06089850Recruiting
Emotional effects of stem cell donation on haploidentical donors
This study looks at the emotional and psychological impact on people who donate stem cells to a family member (a haploidentical donor). It aims to understand how the donation experience affects donors.
ParisAges 18 years+ - NCT04624373Recruiting
Test tumor DNA from breath biopsy samples
This study checks tiny pieces of DNA from a sample taken during a breathing-tube biopsy (EBUS-TBNA) to better identify certain lung cancer changes. It may help doctors learn more about the type of lung cancer and, in some cases, why targeted treatments stop working.
ToulouseAges 18–65 - NCT07232849RecruitingPhase 2
New drug combo for advanced lung cancer
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07230405RecruitingPhase 2
Study of SKB571 for advanced lung cancer
This trial tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it can help shrink tumors or slow cancer growth.
GuangzhouAges 18–75 - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07234409Recruiting
Robotic partial nephrectomy for small kidney tumors
This trial compares different surgical methods for removing kidney tumors using a single-port robot. It aims to find the best approach for treating stage 1 kidney cancer.
MilanAges 18 years+ - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT07234968Recruiting
Stent vs no stent after bladder removal surgery
This study looks at whether leaving a small tube (ureteral stent) in place after bladder removal helps recovery. It compares people who get a stent to those who don't, focusing on problems like leaks or infections after surgery.
Philadelphia, PennsylvaniaAges 18–85 - NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07234656Recruiting
Study on fear of cancer returning in kidney cancer
This study looks at fear of cancer recurrence in people with kidney cancer and their partners. It aims to understand and help manage these fears. You and your partner may join if you had surgery for early-stage kidney cancer.
AalborgAges Any age - NCT06760039RecruitingPhase 1/Phase 2
Comparing R-CMOP and R-CHOP for first-time DLBCL treatment
This trial tests if a new drug combination (R-CMOP) works as well as or better than the usual combination (R-CHOP) for people with a type of lymphoma called DLBCL who haven't had treatment yet.
Fuzhou, FujianAges 18–80 - NCT06908902Recruiting
Robot-assisted kidney surgery for early-stage tumors without clamping
This study tests a robot-assisted surgery to remove part of the kidney for T1 tumors without clamping the main artery, which may help preserve kidney function. It may be an option for patients who are healthy enough for major surgery and have a small, early-stage kidney tumor.
Nanjing, JiangsuAges 18–80 - NCT04412187Recruiting
Study of inflammation after a new stroke
This study looks at inflammation-related changes soon after an acute ischemic stroke (a type caused by a blocked blood vessel). It may help researchers understand what factors drive recovery and how they could be targeted in the future.
Munich, GermanyAges 50 years+ - NCT06911606RecruitingPhase 2
Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT07222111Recruiting
Dried plums for immune health in postmenopausal women
This study tests whether eating dried plums every day can improve immune function in women after menopause. Participants will eat dried plums and provide stool samples at four times during the study.
Indianapolis, IndianaAges 60–75 - NCT07225036Recruiting
Low-dose liver radiation to boost immunotherapy
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
Cincinnati, OhioAges 18 years+ - NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.